Core Viewpoint - Addex Therapeutics announced that its spin-out company, Neurosterix, has initiated a Phase 1 clinical study of NTX-253, a positive allosteric modulator for the treatment of schizophrenia, marking a significant milestone for both companies [1][2]. Company Overview - Addex Therapeutics is a clinical-stage biopharmaceutical company focused on developing novel small molecule allosteric modulators for neurological disorders [4]. - The company retains a 20% equity interest in Neurosterix, which was spun out in April 2024 and raised $65 million in Series A financing [2][4]. Product Development - NTX-253 is a selective, orally available positive allosteric modulator of the muscarinic M4 receptor, designed to treat schizophrenia by potentially reducing psychosis symptoms without the side effects associated with traditional dopamine antagonists [1][3]. - Preclinical studies have shown that NTX-253 has robust antipsychotic-like activity and a favorable safety profile, supporting its advancement into first-in-human clinical studies [3]. Market Position - The M4 muscarinic receptor is recognized as a validated target for treating schizophrenia, offering a novel therapeutic approach compared to existing dopamine receptor antagonists [3]. - Current antipsychotics primarily target dopamine receptors, which can lead to metabolic, cognitive, and motor side effects, highlighting the potential advantages of M4 PAMs like NTX-253 [3].

Core Insights - Addex Therapeutics is a clinical-stage biopharmaceutical company focused on developing novel small molecule allosteric modulators for neurological disorders [4] - The company announced the presentation of preclinical data for its GABAB positive allosteric modulator cough program at the 10th American Cough Conference [1][2] Company Overview - Addex's lead drug candidate is dipraglurant, a negative allosteric modulator targeting mGlu5, currently under evaluation for brain injury recovery [4] - The company is advancing an independent GABAB PAM program specifically for chronic cough, while also collaborating with Indivior on a GABAB PAM drug candidate for substance use disorders [4] - Addex holds a 20% equity interest in Neurosterix LLC, which is developing a portfolio of allosteric modulator programs for various neurological conditions [4] Presentation Details - The presentation will be led by Mikhail Kalinichev, Head of Translational Science, discussing the antitussive efficacy of Compound A in guinea pig models [2][3] - The presentation is scheduled for June 7, 2025, at 11:20 am EST [7] Scientific Background - GABAB receptors are crucial in the cough neural circuit and are activated by the neurotransmitter GABA [3] - Current treatments like baclofen have limitations, and targeting allosteric sites may offer advantages such as higher selectivity and better tolerability [3]

Core Insights - Addex Therapeutics announced that its partner Indivior has successfully advanced the GABAB positive allosteric modulator (PAM) program through IND enabling studies, marking the final preclinical development stage before clinical studies can commence [1][2] - Addex is eligible for payments up to USD 330 million based on the achievement of regulatory, clinical, and commercial milestones, along with tiered royalties on net sales ranging from high single digits to low double digits [2] Company Overview - Addex Therapeutics is a clinical-stage biopharmaceutical company focused on developing novel small molecule allosteric modulators for neurological disorders [4] - The company's lead drug candidate, dipraglurant, is under evaluation for brain injury recovery, including post-stroke and traumatic brain injury recovery [4] - Addex holds a 20% equity interest in Neurosterix LLC, which is advancing a portfolio of allosteric modulator programs for various neurological conditions [4] GABAB PAM Program - The GABAB PAM program is aimed at treating substance use disorders and has successfully completed preclinical safety and toxicity studies [2][3] - The activation of the GABAB receptor is clinically validated, with existing agonists like baclofen showing efficacy in multiple disease areas, although their use is limited due to side effects [3] - Novel PAMs are expected to provide efficacy with fewer adverse effects and less tolerance compared to direct agonists [3]

TABLE OF CONTENTS As filed with the Securities and Exchange Commission on June 1, 2023. Registration Statement No. 333-271611 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Amendment No. 2 Copies to: to Form F-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Addex Therapeutics Ltd (Exact name of registrant as specified in its charter) 2834 Switzerland (State or other jurisdiction of incorporation or organization) (Primary Standard Industrial Classification Code Number) Chem ...

TABLE OF CONTENTS As filed with the Securities and Exchange Commission on May 3, 2023. Registration Statement No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form F-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Addex Therapeutics Ltd (Exact name of registrant as specified in its charter) Switzerland (State or other jurisdiction of incorporation or organization) 2834 (Primary Standard Industrial Classification Code Number) Chemin des Mines 9, CH-1202 Geneva, Switz ...